OraSure Technologies (OSUR) Set to Release Quarterly Earnings on Monday

OraSure Technologies (NASDAQ:OSUR) is expected to release its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect OraSure Technologies to announce earnings of ($0.18) per share and revenue of $31.00 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 9, 2026 at 5:00 PM ET.

OraSure Technologies Stock Performance

Shares of OSUR stock opened at $3.44 on Friday. The stock’s fifty day moving average is $3.73 and its 200-day moving average is $3.53. The stock has a market capitalization of $237.26 million, a PE ratio of -4.99 and a beta of 1.08. OraSure Technologies has a 52 week low of $2.08 and a 52 week high of $4.58.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Craig Hallum raised OraSure Technologies to a “strong-buy” rating in a report on Friday, October 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of OraSure Technologies in a report on Tuesday, September 1st. Zacks Research raised shares of OraSure Technologies to a “hold” rating in a report on Friday, October 2nd. Finally, Wall Street Zen upgraded shares of OraSure Technologies from a “sell” rating to a “hold” rating in a research report on Monday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $3.00.

About OraSure Technologies

OraSure Technologies, Inc develops, manufactures and markets diagnostic products and specimen-collection technologies used by healthcare providers, laboratories, researchers and consumers. The company focuses on making testing more accessible through products that support decentralized, point-of-care and at-home testing, as well as laboratory-based molecular and diagnostic workflows.

Its portfolio has included the OraQuick line of rapid diagnostic tests, including oral-fluid tests for HIV and hepatitis C, along with other infectious-disease testing products.